Clinical utility of RD1, RD9 and hsp65 based PCR assay for the identification of BCG in vaccinated children

Jeanette WP Teo*, Janet WS Cheng, Roland Jureen and Raymond TP Lin

Abstract

Background: Mycobacterium bovis Bacille Calmette-Guérin (BCG) vaccine is widely administered to prevent tuberculosis. Vaccine complications are rare. However, when BCG-related adverse reactions arise there is a need to rapidly and reliably identify BCG from other members of the Mycobacterium tuberculosis complex (TBC). PCR assays based on the detection of the regions of difference (RD), in particular RD1 and RD9, have been invaluable in the identification of BCG. Prior to this study, specimens were identified through HPLC analysis at a local reference laboratory taking up to 2 weeks for a result. We sought to expedite the identification process by validating a RD1, RD9 and hsp65 PCR assay for the identification and differentiation of BCG from TBC.

Findings: In the past 3 years, we validated the RD1, RD9 and hsp65 PCR assay for 16 mycobacterial isolates obtained from children who had experienced adverse reactions to BCG vaccination. In these cases, the clinician required a definitive identification of the isolate. The RD1 and RD9 PCR profiles indicated that all 16 isolates were BCG whilst amplification of the hsp65 target functioned as a PCR positive control. When tested against clinical M. tuberculosis (MTB), reference and non-tuberculous mycobacteria the PCR assay demonstrated 100% sensitivity and specificity.

Conclusions: The RD1, RD9 and hsp65 PCR assay is a useful tool for the rapid and reliable identification of BCG. Its ease of use has allowed it to be implemented in our clinical microbiology laboratory.

Keywords: Mycobacterium bovis, Bacille Calmette-Guérin (BCG), Adverse reaction, PCR

Findings

Mycobacterium bovis Bacille Calmette-Guérin (BCG) vaccine has been used extensively for almost the last 100 years for the prevention of TB. In countries with a national childhood immunization program, vaccination rates typically exceed >80% in neonates and infants [1]. In Singapore, BCG vaccination is given to all newborns since 1957 and has contributed to an effective TB Control Programme.

The BCG vaccine is regarded as safe. There is a very low incidence of complications, ranging from 0.1 to 5 per 1000 vaccinated [2,3]. BCG-induced adverse events can be broadly classified into local or disseminated disease ranging from sub-cutaneous abscess and keloids, lymphadenopathy, supplicative lymphadenitis to systemic events such as osteitis and disseminated BCG disease [3,4]. The risk of disseminated BCG disease escalates in HIV-infected children [5]. Chemotherapy with anti-tuberculosis drugs may be initiated to prevent further progression to disseminated disease however treatment is complicated by the inherent resistance of all M. bovis strains to pyrazinamide [5,6]. Therefore, it is imperative to accurately identify and differentiate M. bovis BCG particularly from M. tuberculosis.

The diagnostics of BCG is not straightforward. M. bovis BCG belongs to the Mycobacterium tuberculosis complex (TBC) of highly related organisms comprising M. tuberculosis, M. africanum, M. bovis, M. microti and M. canetti. The lack of clear-cut differentiation between the members [7] impedes the identification of BCG. Limited methods avail for the differentiation of members of the TBC. Phenotypic biochemical assays can be highly subjective making it unreliable for identification [8]. High performance liquid chromatography (HPLC) analysis can
separate BCG vaccine strains from *M. tuberculosis* and *M. bovis* [9]. However, this approach is not pragmatic for the routine diagnostic laboratory due to requirement of specialized equipment and protracted turnaround times.

Comparative genomics has revealed 16 regions of difference (RD) in *M. bovis* and *M. bovis* BCG strains, which are absent in *M. tuberculosis* H37Rv. Regions RD1, RD9, RD10 have been extensively studied. Their exclusive absence in all BCG vaccine strains and presence in TB strains makes these loci reliable and accurate diagnostic markers [10,11]. Deletion profiles based on these RD regions have been employed successfully for the differentiation of BCG and TB via PCR based approaches [12-14].

This study was initiated three years ago, in 2010, when we sought to evaluate a PCR approach for the rapid identification of BCG that would be suitable for implementation in our routine diagnostic microbiology laboratory. Prior to this, specimens were identified through HPLC analysis at a local reference laboratory. Here, we describe the clinical performance of the PCR assay based on the detection of RD1 and RD9 regions for the identification and differentiation of BCG from MTB.

Bacterial isolates used in the study comprised reference strains and clinical isolates (Table 1). Reference mycobacterial isolates were from the American Type Culture Collection (ATCC, Manassas, VA, USA) and non-mycobacterial quality control strains *Rhodococcus equi* and *Nocardia farcinica* were from our laboratory. Clinical mycobacterial specimens were obtained from (i) patients deemed to have adverse reactions to BCG immunization hence requiring specimens were obtained from (i) patients deemed to have adverse reactions to BCG immunization hence requiring definitive identification of the mycobacterial isolate (*n*=16), (ii) patients with confirmed TB (*n*=32). The diagnosis of tuberculosis was based on clinical and microbiological findings whereby the cultures were positive for *M. tuberculosis* by the Xpert MTB/RIF real-time PCR assay (Cepheid, Sunnyvale, CA) [15]. The isolation of clinical mycobacterial isolates from patient specimens is described below. Ethical approval was not required as the study was conducted for the improvement of a public health service and in a manner that subjects could not be identified.

Respiratory and non-respiratory specimens (including pus and aspirate samples) were decontaminated according to standard methods using N-acetyl-L-cysteine–sodium hydroxide (NALC-NaOH) [16]. Tissue specimens were thoroughly minced using a pair of sterile scissors before the NALC-NaOH processing. Sediment from the specimen obtained by centrifugation at 3600 rpm for 15 min was resuspended in phosphate-buffered saline pH 6.8 to a final volume of 1.5 ml. Half of the sediment was used for inoculation into the automated Mycobacteria Growth Indicator Tube [MGIT; (Becton Dickinson, Cockeysville, MD)] culture system and the other half was inoculated into a Lowenstein-Jensen (LJ) slant. Cultures were incubated at 37°C for 6 weeks in MGIT and 8 weeks on LJ slants at 37°C and 5% CO₂. Prior to transporting the pure mycobacterial cultures out of the Biosafety Level 3 Laboratory, the bacteria were killed by resuspending colonies in 500 μl of boiled culture supernatant (above). For each isolate tested, three sets of PCR reactions were setup enabling the detection of RD1, RD9 and *hsp65* (Table 2). The amplification of a 401 bp fragment from *hsp65* served as a PCR positive control for members of the MTB complex. PCR amplification reactions were performed using HotStarTaq master mix kit (Qiagen, Hilden, Germany) with an initial denaturation at 95°C for 5 min, followed by 35 temperature cycles of heat denaturation at 94°C for 30 s, primer annealing at 62°C for 90 s and extension at 72°C for 60 s and a final step of extension at 72°C for 10 min. PCR products were separated by electrophoresis in 1.5% agarose gel, stained with ethidium bromide and visualized by UV transillumination. The results were positive when the specific size product was observed (Table 2).

Additional tests used for the identification of members of TBC include (i) AccuProbe Mycobacterium Tuberculosis Complex Culture Identification Test (Gen-Probe Incorporated, San Diego, CA) is a rapid DNA probe test utilizing nucleic acid hybridization for the identification of TBC isolated from culture. Testing was performed in accordance with the manufacturer’s instructions. Briefly, after bacterial lysis, a 100 μl sample was transferred to the corresponding AccuProbe tube. Hybridization results, expressed as relative light units (RLUs), were determined with a Leader 50 luminometer (GenProbe). A positive reaction was a result > 30000 RLU. (ii) SD TB Ag MPT64 Rapid (Standard Diagnostics, Seoul, South Korea) is an immunochromatographic test using anti-MPT64 antibodies for the detection of the MPT64 antigen of MTB isolates. The assay is used primarily to distinguish between *M. tuberculosis* complex and non-tuberculous mycobacteria (NTM). The kit was used according to the manufacturer’s protocol. Briefly, 100 μl of condensation fluid from colonies growing in LJ slants were applied directly to the sample well. Tests were interpreted 15 min after sample application. The presence of only a control band alone indicated a negative result whereas the appearance of a second band (test band) indicated a positive result for MTB. (iii) *oxyR* sequencing. A single nucleotide polymorphism in position 285 of the *oxyR* sequence allows differentiation of *M. bovis* from the other members of the TBC. All *M. bovis* strains have an adenine (A) residue at nucleotide 285, whereas all *M. tuberculosis* strains have guanine (G) residue at this position [14,17]. A 548 bp
| Samples | Disease description and management | Specimen site | PCR RD1 | PCR RD9 | PCR oxyR+ | SD TB Ag MPT64 Rapid test | AccuProbe Complex test |
|---------|----------------------------------|---------------|---------|---------|-----------|---------------------------|-----------------------|
| For BCG identification (n=16) Case/Sex/Age (months) | | | | | | | |
| 1/M/3 | BCG adenitis. Excision of inguinal lymph node | Inguinal lymph node | — | — | + | M. bovis | NEG | ND |
| 2/M/2 | Incision and drainage of abscess | Axillary abscess | — | — | + | M. bovis | NEG | POS |
| 3/M/2 | No information available | Axillary abscess | — | — | + | M. bovis | NEG | POS |
| 4/F/4 | Incision and drainage of gluteal abscess | Injection site abscess | — | — | + | M. bovis | NEG | POS |
| 5/M/3 | BCG adenitis. Excision of inguinal lymph node | Inguinal lymph node | — | — | + | M. bovis | NEG | POS |
| 6/F/3 | No information available | Inguinal lymph node | — | — | + | M. bovis | NEG | POS |
| 7/M/3 | No information available | Inguinal lymph node | — | — | + | M. bovis | NEG | POS |
| 8/F/3 | No information available | Inguinal lymph node | — | — | + | M. bovis | NEG | POS |
| 9/M/4 | BCG adenitis. Excision of inguinal lymph node | Injection site abscess | — | — | + | M. bovis | NEG | POS |
| 10/M/22 | No information available | Lymph node | — | — | + | M. bovis | NEG | POS |
| 11/M/2 | No information available | Lymph node | — | — | + | M. bovis | NEG | POS |
| 12/F/3 | Left caseating inguinal lymph node. | Lymph node | — | — | + | M. bovis | NEG | POS |
| 13/M/3 | No information available | Inguinal lymph node | — | — | + | M. bovis | NEG | POS |
| 14/M/4 | Left axillary lymph node abscess. Incision and drainage | Axillary abscess | — | — | + | M. bovis | NEG | POS |
| 15/M/3 | No information available | Lymph node abscess | — | — | + | M. bovis | NEG | POS |
| 16/M/3 | No information available | Inguinal lymph node aspirate | — | — | + | M. bovis | NEG | POS |

For specificity and sensitivity testing

Clinical MTB isolates (n= 32) Respiratory and non-respiratory + + + ND POS POS

M. tuberculosis complex control strains (n=3)

M. bovis BCG Pasteur ATCC 35734 | NA | — | — | + | M. bovis | NEG | POS |
M. tuberculosis H37Ra ATCC 25177 | NA | + | + | + | MTB | POS | POS |
M. tuberculosis H37Rv ATCC 27294 | NA | + | + | + | MTB | POS | POS |

Non M. tuberculosis strains (n=13)

M. intracellulare ATCC 13950 | NA | — | — | — | ND | ND- | ND |
M. gordonae ATCC 35756 | NA | — | — | — | ND | ND | ND |
M. kansasii ATCC12478 | NA | — | — | — | ND | ND | ND |
| Specimen     | Characteristics | PCR Amplification | oxyR | oxyR 285 G→A |
|--------------|-----------------|-------------------|------|--------------|
| M. septicum ATCC 700731 | NA              | —                 | —    | —            |
| M. senegalense ATCC 35755 | NA              | —                 | —    | —            |
| M. perigrinum ATCC 23001 | NA              | —                 | —    | —            |
| M. xenopi ATCC 19250 | NA              | —                 | —    | —            |
| M. abscessus ATCC 19977 | NA              | —                 | —    | —            |
| M. chelonae ATCC 19539 | NA              | —                 | —    | —            |
| M. fortuitum ATCC 6841 | NA              | —                 | —    | —            |
| M. haemophilum ATCC 29548 | NA              | —                 | —    | —            |
| Rhodococcus equi | NA              | —                 | —    | —            |
| Nocardia farcinica | NA              | —                 | —    | —            |

ND: Not done.
NA: Not applicable.
—: No PCR amplification observed.
+: Positive PCR amplification.

oxyR: A single nucleotide polymorphism, G→A at position 285, revealed by oxyR sequencing differentiates M. bovis and TBC.
fragment of oxyR was amplified using the primer set listed in Table 2. The PCR conditions used were based on a published PCR protocol [17]. The amplicon was purified using QIAquick PCR Purification Kit (Qiagen, Hilden, Germany) and sequenced using the same set of primers.

The administration of the BCG vaccine rarely causes complications. Mild injection site reactions are almost universal upon vaccination, often taking the form of a papule or scarring. Typically no treatment is required. Severe local and systemic BCG-induced disease is a much less frequent occurrence and may necessitate the initiation of treatment with anti-tuberculosis drugs [3,4]. Hence, it is critical to have rapid and accurate tests that can detect M. bovis BCG and differentiate it from MTC so that the clinician can choose the appropriate treatment.

Over the last 3 years, there were 16 cases submitted to our laboratory requesting the differentiation of BCG from MTB. BCG induced disease was suspected as adverse reactions arose shortly after vaccination and in close proximity to the injection site. Clinical descriptions of the cases where available are indicated on Table 1. In all cases with surgical intervention, the patients healed well.

Molecular assays based on the RD deletion profiles have been invaluable in differentiating members of the TBC [12-14]. The complete absence of both RD1 and RD9 is indicative of M. bovis BCG, conversely the presence of both RD1 and RD9 indicates M. tuberculosis. Non-BCG M. bovis is distinguished from BCG by the presence of RD1 and the absence of RD9 [12-14]. In this study, none of the 16 isolates submitted for testing were positive for RD1 or RD9, indicating they were M. bovis BCG. These PCR results confirmed suspicions of BCG-related disease in the recently vaccinated children (Table 1).

The SD TB Ag MPT64 Rapid test. The AccuProbe Mycobacterium tuberculosis complex test and the clinical TB cases tested positive with this kit (Table 1). The oxyR polymorphism however does not make a distinction between BCG and non-BCG M. bovis. Based on patient clinical history and the fact that zoonotic M. bovis infections would be almost non-existent in a non-cattle farming setting such as ours [18], M. bovis BCG would be the presumptive identification.

Distinguishing BCG from M. bovis is not a simple task. Phenotypically both species are susceptible to thiophene-2-carboxylic acid hydrazide and resistant to pyrazinamide although M. bovis has a preference for microaerophilic conditions compared to BCG which displays aerophilic growth (13). HPLC analysis of mycolic acid esters can be used for confirmation of BCG strains as it possesses a profile that is unique from M. bovis however it is a method that is restricted to being carried out at a mycobacterial reference laboratory (9). Comparatively, molecular testing offers accessibility and rapidity. Apart from the exploitation of RD profiles for species differentiation, the size-variable senX3-regX3 intergenic region has also been targeted [19]. PCR assays that utilize the senX3-regX3 intergenic region are also typically used in conjunction with the RD targets thereby underscoring the importance of RD for differentiating TBC members [20].

Other tests routinely performed in our laboratory for the identification of members of the TBC include the AccuProbe Mycobacterium tuberculosis complex test and the SD TB Ag MPT64 Rapid test. The AccuProbe Mycobacterium tuberculosis complex test is used for the identification of TBC members and as anticipated it did not differentiate between BCG and TB. All the BCG cases as well as the clinical TB cases tested positive with this kit (Table 1). The SD TB Ag MPT64 Rapid is an immunochromatographic test detecting MPT64, an antigen secreted by members of the TBC. Most BCG vaccine strains do not secrete MPT64 nevertheless exceptions have been noted [21,22]. Strains like BCG Tokyo and BCG Russia still retain the gene for MPT64 and the capacity to secrete the antigen [21,23]. These vaccines strains could still test
positive on the SD TB Ag MPT64 Rapid test. All our MTB isolates gave positive results with the SD TB Ag MPT64 Rapid test. In contrast, all the BCG suspected cases tested negative (Table 1). In Singapore, since June 2003, BCG Danish strain 1331 has been the sole vaccine type [24]. This strain lacks MPT64 [23] and will therefore be negative on the SD TB Ag MPT64 Rapid test.

Prior to establishment of the PCR assay, specimens for BCG confirmation were sent to a reference laboratory for HPLC analysis. Here, we present evaluation data demonstrating the clinical validity of the RD1, RD9 and hsp65 based PCR assay for the rapid detection and differentiation of M. bovis BCG. Its reliability and ease of use has made it feasible for incorporation as a routine mycobacterial diagnostic service in our laboratory.

This work was supported by a Health Service Development Programme Grant provided by the Ministry of Health, Singapore (Grant # HSDP06/X04).

Competing interests

In the past 5 years none of the authors have received reimbursements, fees, funding or salary from any organization that may in any way gain or lose financially from the publication of this manuscript either now or in the future. In addition there is no non-financial competing interest to declare in relation to this manuscript.

Authors’ contributions

JT, JC, RJ, RL conceived and participated in the study design, results analysis and the preparation of the manuscript. JT and JC performed the experiments in this study. All authors read and approved the final manuscript.

Received: 9 July 2013 Accepted: 23 October 2013
Published: 29 October 2013

References

1. World health organization (WHO): Global tuberculosis report, 2012. http://www.who.int/tb/publications_global_report/tbr12_main.pdf.
2. Lotte A, Wasz-Hockert O, Poisson N, Engbaek H, Landmann H, Quast U, Andrasofszky B, Lugosi I, Vadasz I, Mihaliscu P: Review Second IUATLD study on complications induced by intradermal BCG-vaccination. Bull Int Union Tuberc Lung Dis 1986, 63(2):67–59.
3. World Health Organization (WHO): Information sheet – Observed rate of vaccine reactions Bacille Calmette-Guérin (BCG) vaccine 2012. http://www.who.int/vaccine_safety/initiative/tools/BCG_Vaccine_rates_information_sheet.pdf.
4. Murphy D, Corner LA, Gormley E: Adverse reactions to Mycobacterium bovis bacille Calmette-Guérin (BCG) vaccination against tuberculosis in humans, veterinary animals and wildlife species. Tuberculosis (Edinb) 2008, 88(6):344–357.
5. Hesseling AC, Schaaf HS, Vctor T, Beyers N, Marais BI, Cotton MF, Wid I, Gie RP, van Heldens P, Warren RM: Resistant Mycobacterium bovis bacillus calmette-Guérin disease: implications for management of Bacillus Calmette-Guérin Disease in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2004, 23(5):476–479.
6. Cuello-Garcia CA, Pérez-Gaxiola G, Jiménez Gutierrez C: Treating BCG-induced disease in children. Cochrane Database Syst Rev 2013, 1. Article No. CD008300.
7. Tsukamura M, Mizuno S, Toyama H: Taxonomic studies on the Mycobacterium tuberculosis series. Microbiol Immunol 1985, 29(4):285–299.
8. Kent PT, Kubica GP: Public health mycobacteriology: a guide for the level III laboratory. Atlanta, Ga: Centers for Disease Control, Public Health Service, U.S. Dept. of Health and Human Services; 1985.
9. Floyd MM, Silcox VA, Jones WD Jr, Butler WR, Kilburn JR: Comparison of Mycobacterium bovis BCG from Mycobacterium tuberculosis and Mycobacterium bovis by using high-performance liquid chromatography of mycolic acids. J Clin Microbiol 1992, 30(5):1327–1330.
10. Brosch R, Gordon SV, Marmiesse M, Brodin P, Buchrieser C, Eiglemeier K, Garnier T, Gutierrez C, Hewinson G, Kremer K, Parsons LM, Pym AS, Samper S, van Sooilingen D, Cole ST: A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proc Natl Acad Sci U S A 2002, 99(6):3684–3689.
11. Behr MA, Wilson MA, Gill WP, Salamon H, Schonlikn GK, Rane S, Small PM: Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 1998, 284(5419):1520–1523.
12. Talbot EA, Williams DL, Frothingham R: PCR identification of Mycobacterium bovis BCG. J Clin Microbiol 1997, 35(3):566–569.
13. Parsons LM, Brosch R, Cole ST, Somoskovi A, Loder A, Bretzel G, Van Sooilingen D, Hale VM, Saffinger M: Rapid and simple approach for identification of Mycobacterium tuberculosis complex isolates by PCR-based genomic deletion analysis. J Clin Microbiol 2002, 40(7):2339–2345.
14. Huard RC, Lazzarini LC, Butler WR, van Sooilingen D, Ho JIL: PCR-based method to differentiate the subspecies of the Mycobacterium tuberculosis complex on the basis of genomic deletions. J Clin Microbiol 2003, 41(4):1637–1650.
15. Teo J, Jurteen R, Zhang D, Chan D, Lin R: Comparison of two nucleic acid amplification assays, the Xpert MTB/RIF assay and the amplified Mycobacterium Tuberculosis Direct assay, for detection of Mycobacterium tuberculosis in respiratory and nonrespiratory specimens. J Clin Microbiol 2011, 49(10):3659–3662.
16. Merichick B, Nolte F, Wallace R Jr: Mycobacterium. In Manual of clinical microbiology. Edited by Murray PR, Baron EJ, Jorgensen JH, Landby ML, Pfaller MA. Washington, DC: ASM Press; 2007.
17. Sreevatsan S, Escalante P, Pan X, Gilleis DA 2nd, Siddiqui S, Khalaf CN, Kreiswirth BN, Bifani P, Adams LG, Ficht T, Perumalla VS, Cave MD, van Embden JD, Musser JM: Identification of a polymorphic nucleotide in hsp65 specific for Mycobacterium bovis. J Clin Microbiol 1995, 33(10):2007–2010.
18. Lobue PA, Enrason DA, Thoen CO: Tuberculosis in humans and animals: an overview. Int J Tuberc Lung Dis 2010, 14(9):1075–1078.
19. Magdalena J, Supply P, Locih C: Specific differentiation between Mycobacterium bovis BCG and virulent strains of the Mycobacterium tuberculosis complex. J Clin Microbiol 1998, 36(9):2471–2476.
20. Bedwell J, Kario SK, Behr MA, Bygraves JA: Identification of subarstains of BCG vaccine using multiplex PCR. Vaccine 2001, 19(15–16):2146–2151.
21. Li H, Ulstrup JC, Jonassen TO, Melby K, Nagai S, Harboe M: Evidence for absence of the MPB64 gene in some strains of Mycobacterium bovis BCG. Infect Immun 1993, 61(5):1730–1734.
22. Hasegawa N, Muram T, Ishi K, Yamaguchi K, Lindner TH, Mentis S, Matthews JD, Siddiqi SJ: New simple and rapid test for culture confirmation of Mycobacterium tuberculosis complex: a multicenter study. J Clin Microbiol 2002, 40(3):908–912.
23. Behr MA: BCG--different strains, different vaccines? Lancet Infect Dis 2002, 2(10):869–912.
24. Health Science Authority: Singapore. Product safety alerts 2011:Reports of lymphadenitis following administration of BCG Vaccine 35P. http://www.hsa.gov.sg/publish/hsaportal/en/health_products_regulation/safety_information/product_safety_alerts/safety_alerts_2011/reports_of_lymphadenitis.html.

doi:10.1186/1756-0500-6-434

Cite this article as: Teo et al.: Clinical utility of RD1, RD9 and hsp65 based PCR assay for the identification of BCG in vaccinated children. BMC Research Notes 2013 6:434.